No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease

• References

• 1 Cranenburg EC, Schurgers LJ, Vermeer C. Vitamin K: the coagulation vitamin that became omnipotent. Thromb Haemost 2007; 98: 120-125.
• 2 Luo G, Ducy P, McKee MD. et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81.
• 3 Herrmann SM, Whatling C, Brand E. et al. Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20: 2386-2393.
• 4 Wang Y, Zhen Y, Shi Y. et al. Vitamin k epoxide reductase: a protein involved in angiogenesis. Mol Cancer Res 2005; 3: 317-323.
• 5 Rost S, Fregin A, Ivaskevicius V. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-541.
• 6 Bodin L, Horellou MH, Flaujac C. et al. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J Thromb Haemost 2005; 3: 1533-1535.
• 7 Rieder MJ, Reiner AP, Gage BF. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
• 8 Geisen C, Watzka M, Sittinger K. et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005; 94: 773-779.
• 9 Bodin L, Verstuyft C, Tregouet DA. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-140.
• 10 Oldenburg J, Bevans CG, Fregin A. et al. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98: 570-578.
• 11 Siguret V. Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy. Pathol Biol (Paris) 2007; 55: 295-298.
• 12 Loriot MA, Beaune P. Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies. Rev Med Interne 2006; 27: 979-982.
• 13 Wang Y, Zhang W, Zhang Y. et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 2006; 113: 1615-1621.
• 14 Lacut K, Larramendy-Gozalo C, Le Gal G. et al. Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study. J Thromb Haemost 2007; 5: 2020-2024.
• 15 Watzka M, Nebel A, El Mokhtari NE. et al. Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans. Thromb Haemost 2007; 97: 998-1002.
• 16 Hindorff LA, Heckbert SR, Smith N. et al. Common VKORC1 variants are not associated with arterial or venous thrombosis. J Thromb Haemost 2007; 5: 2025-2027.
• 17 Reny JL, Alhenc-Gelas M, Fontana P. et al. The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: results of a case-control study. J Thromb Haemost 2004; 2: 1334-1340.
• 18 Fontana P, Gaussem P, Aiach M. et al. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 2003; 108: 2971-2973.